Medical products company ResMed says it lifted revenue in the three months ended March 31 by 12 per cent, to $US662.2 million ($A952.2 m).
Resmed said it made $US157 million ($224m) in profit, up 15 per cent from the same period in 2018.
The board of directors declared a quarterly cash dividend of 37 US cents per share.
At 1029 AEST, Resmed shares were up 92 cents, or 6.25 per cent, to $15.74, their highest level since January.
The San Diego-based, ASX-listed company produces products to treat sleep disorders.